Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cozymin
- Development stage
- Unknown
- Lead developer
- Unimarck Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intranasal
01
Overview
Cozymin is a brand name for a line of multi-symptom cough, cold, and allergy medications marketed by Unimarck Pharma in India. The most common formulation, Cozymin Tablet, is a fixed-dose combination of the second-generation antihistamine cetirizine, the analgesic and antipyretic paracetamol (acetaminophen), and the nasal decongestant phenylephrine. Other formulations under the Cozymin brand include Cozymin Syrup (chlorpheniramine and menthol), Cozymin Forte Suspension/Drops (chlorpheniramine, paracetamol, and phenylephrine), and Cozymin DX Syrup (chlorpheniramine, dextromethorphan, and phenylephrine). These products are indicated for the symptomatic relief of the common cold, allergic rhinitis, nasal congestion, fever, and associated headaches or body aches.
- Brand names
- CozyminCozymin DXCozymin ForteCozymin+
- Other names
- cetirizine + paracetamol + phenylephrinechlorpheniramine + dextromethorphan + phenylephrinechlorpheniramine + mentholchlorpheniramine + paracetamol + phenylephrine
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)NMDAR (Glutamate receptor ionotropic, NMDA)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on Cozymin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cozymin.